Histamont-L Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, mitigating inflammation and bronchoconstriction associated with allergic responses. The synergistic effect of these agents provides comprehensive relief from allergic symptoms by targeting multiple inflammatory pathways. Histamont-L is indicated for patients requiring both antihistaminic and leukotriene-modifying therapy, particularly in cases where monotherapy is insufficient. It is generally well-tolerated, with common adverse effects including headache, fatigue, and gastrointestinal discomfort. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision in pediatric and elderly populations. Histamont-L Tablet should be administered orally once daily, preferably in the evening, to optimize efficacy and adherence. This combination therapy offers an effective option for long-term management of allergic disorders, enhancing patient quality of life through symptom control and prevention of exacerbations.